156 related articles for article (PubMed ID: 36760683)
21. A novel cuproptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma.
Yang F; Jiang S; Liu Y; Zhang T; Zhu C; Zhang L; Sang X; Lu X; Wei J; Deng K; Zheng Y; Xu Y
Heliyon; 2022 Nov; 8(11):e11768. PubMed ID: 36468143
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
23. MCM10 Acts as a Potential Prognostic Biomarker and Promotes Cell Proliferation in Hepatocellular Carcinoma: Integrated Bioinformatics Analysis and Experimental Validation.
Wan W; Shen Y; Li Q
Cancer Manag Res; 2020; 12():9609-9619. PubMed ID: 33116820
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
25. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma.
Zhu H; Mao F; Wang K; Feng J; Cheng S
Front Genet; 2022; 13():972212. PubMed ID: 36212138
[TBL] [Abstract][Full Text] [Related]
27. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients.
Ye D; Liu Y; Li G; Sun B; Peng J; Xu Q
Front Oncol; 2021; 11():766072. PubMed ID: 34868990
[TBL] [Abstract][Full Text] [Related]
28. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
29. Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation.
Liu Y; Cao Y; Cai W; Wu L; Zhao P; Liu XG
PeerJ; 2020; 8():e9100. PubMed ID: 32377460
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.
Zhou Z; Zhou Y; Liu D; Yang Q; Tang M; Liu W
Front Pharmacol; 2022; 13():1074123. PubMed ID: 36588699
[TBL] [Abstract][Full Text] [Related]
31. A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy.
Wang XX; Wu LH; Ji H; Liu QQ; Deng SZ; Dou QY; Ai L; Pan W; Zhang HM
Front Mol Biosci; 2022; 9():1001788. PubMed ID: 36250008
[No Abstract] [Full Text] [Related]
32. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients.
Huang S; Li D; Zhuang L; Zhang J; Wu J
Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive multiomics analysis of cuproptosis-related gene characteristics in hepatocellular carcinoma.
Fu J; Wang S; Li Z; Qin W; Tong Q; Liu C; Wang Z; Liu Z; Xu X
Front Genet; 2022; 13():942387. PubMed ID: 36147507
[No Abstract] [Full Text] [Related]
34. A Cuproptosis-Related Gene Model For Predicting the Prognosis of Clear Cell Renal Cell Carcinoma.
Mei W; Liu X; Jia X; Jin L; Xin S; Sun X; Zhang J; Zhang B; Chen Y; Che J; Ma W; Ye L
Front Genet; 2022; 13():905518. PubMed ID: 36092880
[TBL] [Abstract][Full Text] [Related]
35. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
36. Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Li D; Cheng X; Zheng W; Chen J
Cancer Manag Res; 2020; 12():4923-4935. PubMed ID: 32606980
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
[TBL] [Abstract][Full Text] [Related]
38. Leucine zipper downregulated in cancer 1 may serve as a favorable prognostic biomarker by influencing proliferation, colony formation, cell cycle, apoptosis, and migration ability in hepatocellular carcinoma.
Chen H; Chen S; Chen C; Li A; Wei Z
Front Genet; 2022; 13():900951. PubMed ID: 35957693
[No Abstract] [Full Text] [Related]
39. Construction of a 13-microRNA-based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma.
Zheng Z; Wen Y; Nie K; Tang S; Chen X; Lan S; Pan J; Jiang K; Jiang X; Liu P; Yan Y; Liu F; Liu Y; Li P
Hepatol Res; 2020 Oct; 50(10):1151-1163. PubMed ID: 32567216
[TBL] [Abstract][Full Text] [Related]
40. Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma.
Mo M; Ma X; Luo Y; Tan C; Liu B; Tang P; Liao Q; Liu S; Yu H; Huang D; Zeng X; Qiu X
BMC Cancer; 2022 Oct; 22(1):1098. PubMed ID: 36289466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
